4Filing Date: May 13, 2026

Guardant Health (GH) 4: Talasaz AmirAli sold 50,000 shares of Common Stock at $100.… (May 13, 2026)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001753159-26-000010
Total Value$5.02M
Trades1
Insiders1

Transaction Details

Talasaz AmirAli
Co-Chief Executive Officer, Director·Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust
Sell · Dispose
Common Stock
Shares-50.00K
Price$100.32
Total Value$5.02M
Shares Owned After2.10M
Transaction DateMay 12, 2026
10b5-1
Footnotes ▸

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Post-Transaction Holdings

Talasaz AmirAli · Co-Chief Executive Officer, Director
SecuritySharesChange
Common Stock2.10M-50.00K (-2.33%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-05-12 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: Guardant Health, Inc. (GH) CIK: 0001576280 --- Reporting Owner --- Name: Talasaz AmirAli CIK: 0001753159 Role: Director, Officer (Co-Chief Executive Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-05-12 | Code: S (Open market sale) Shares: -50,000 | Price: $100.32 Total Value: $5,016,000.00 Shares Owned After: 2,096,504 | Ownership: I (Indirect) | Nature: Shares held by Talasaz and Eskandari 2017 Family Trust Footnotes: [F1] Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Footnotes (Complete Index) --- F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. --- Signature --- /s/ /s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz (2026-05-13)

keid analysis is for reference only and does not constitute investment advice.